We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Antigen-Based COVID-19 Rapid Test Format Analyzes 500 Samples per Hour and Detects SARS-CoV-2 Infection in 10 Minutes

By LabMedica International staff writers
Posted on 20 May 2021
Print article
Illustration
Illustration
A new antigen-based detection technique could be used to analyze as many as 500 samples per hour and was able to diagnose a viral infection almost as accurately as PCR tests in a recently completed study.

Researchers at the University of Helsinki (Helsinki, Finland) have developed a new rapid assay principle for viral antigen detection, applying it to diagnosing SARS-CoV-2 infections. The test is based on a phenomenon known as time-resolved Förster resonance energy transfer (TR-FRET), where energy travels between two light-sensitive molecules when they are close enough to each other. TR-FRET makes it possible to measure viral particles or the body’s own proteins by using what are known as ‘mix and read’-type tests on complex biological samples, such as serum or even whole blood. In fact, the researchers have previously applied the procedure in the rapid detection of antibodies.

In practice, the TR-FRET solution of the new SARS-CoV-2 rapid test functions like this: a nasopharyngeal swab taken from the test subject is mixed in a test solution which contains antibodies that recognise the SARS-CoV-2 nucleoprotein or spike protein. The antibodies marked with fluorescent labels bind with SARS-CoV-2 particles, forming molecular assemblies, or complexes, whose existence can be confirmed/detected by using a TR-FRET assay. The results come in roughly 10 minutes later: the formation of any complexes demonstrates, to a high degree of certainty, an infection caused by SARS-CoV-2 in the test subject.

The researchers investigated the functioning of the rapid test using 48 specimens which had been selected on the basis of a positive SARS-CoV2 PCR test, with varying concentrations of viral RNA.

“We demonstrated in our study that a technique based on the TR-FRET phenomenon can be used to diagnose SARS-CoV-2 infections in clinical specimens”, said Jussi Hepojoki, docent of virology and Academy of Finland research fellow at the University of Helsinki. “We demonstrated that the technique we have developed was able to detect almost all positive specimens (37/38), from which we were able to isolate SARS-CoV-2 in cell culture. In other words, the carriers were likely to continue to spread the virus at the time of sample collection.”

In contrast, 10 of the selected group of positive SARS-CoV-2 samples produced a positive result in a PCR test even though virus isolation was no longer possible. None of these samples yielded a positive antigen test result. According to Hepojoki, the PCR tests available are sensitive enough to detect coronavirus even when the sample collection has not been optimal. At the same time, this sensitivity can result in cases of positive PCR test results when the infection itself has been eliminated.

Hepojoki says that another benefit of the new rapid test developed by the researchers is its safety for testers: in practice, the virus becomes inactivated soon after being mixed in the test solution. He says that rapid antigen-based tests could be particularly useful for testing not only travelers, but also people at educational institutions. A TR-FRET reader roughly the size of a desktop computer is needed for the test, making it possible, at least in theory, to carry out testing almost anywhere. In addition to the novel coronavirus, the assay principle can be utilized to detect other respiratory infections or basically any molecule: the only thing needed is an antibody capable of identifying the target molecule.

Related Links:
University of Helsinki

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.